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Abstract 
Pain in the joint is often due to cartilage degeneration and represents a serious medical problem 
affecting people of all ages. Although many, mostly surgical techniques, are currently employed to 
treat cartilage lesions, none has given satisfactory results in the long term. Recent advances in 
biology and material science have brought tissue engineering to the forefront of new cartilage repair 
techniques. The combination of autologous cells, specifically designed scaffolds, bioreactors, 
mechanical stimulations and growth factors together with the knowledge that underlies the 
principles of cell biology offers promising avenues for cartilage tissue regeneration. The present 
review explores basic biology mechanisms for cartilage reconstruction and summarizes the 
advances in the tissue engineering approaches. Furthermore, the limits of the new methods and their 
potential application in the osteoarthritic conditions are discussed. 
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1. Introduction  
The damage and loss of organs and tissues leads to metabolic and structural changes that can 
cause significant morbidity, and decrease the quality of life. Currently employed therapies for the 
treatments of joint tissues loss or disease are unsatisfactory as they rely on metal joints prosthesis 
which offer structural replacement albeit limited functionality. Furthermore, artificial implants lack 
tissue’s physiological activities and often do not provide the lifelong solution for the patient. The 
field of tissue engineering (TE) has emerged over the past decades to improve the treatments for 
tissue and organ failure, [1-3]. 
The goal of TE is to provide living biological/physiological substitutes that could replace 
tissue loss due to disease, congenital abnormalities, or trauma. Ideally, the biological substitute 
should structurally and morphologically resemble native tissue and be able to perform similar 
biological functions. In comparison to artificial implants biologically engineered tissue may offer a 
better long term performance due to the enhanced biocompatibility, integration into surrounding 
tissues, and the ability to remodel according to the body requirements. TE can be broadly defined as 
the structural and functional reconstitution of mammalian tissues where the cells, biomaterials and 
biological cues are combined. TE is a highly multidisciplinary field that combines the knowledge 
from materials science, cell and molecular biology, engineering and medicine. The possibility to 
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apply the TE approach as a treatment for osteoarthritis is even more challenging given that the 
disease affects the entire joint. Therefore, the TE package should combine the restoration of normal 
composition and function of the damaged articular cartilage while avoiding further degeneration of 
cartilage and the surrounding tissue. 
 
2. Hyaline cartilage and chondrogenic pathways 
Articular cartilage is a highly specialized tissue that provides low friction and allows for 
efficient load bearing and distribution. The major constituents comprise specialized cells – 
chondrocytes, embedded in highly hydrated and organized extracellular matrix (ECM) consisting of 
collagens fibers and proteoglycans. The mixture of fluid and matrix provides viscoelastic and 
mechanical properties necessary for efficient function of cartilage tissue. Chondrocytes are the 
single cellular component of hyaline cartilage.  
Under physiological conditions a balance between anabolic and catabolic cell activities 
maintains the structural and functional integrity of the ECM. This constant process is dependent of 
several factors, including growth factors, cytokines, mechanical loading, aging and injury. Articular 
cartilage has no blood vessels, it is not innervated and normal mechanisms of tissue repair perform 
poorly to form only fibrocartilagenous tissue. The existing therapies for cartilage repair are limited 
and physicians are often obliged to wait until the cartilage degeneration reaches the point where a 
partial or total joint replacement can be applied as a treatment.  Nevertheless, depending on the age, 
activity level, and degree of cartilage damage, several methods to decrease pain and attempt 
cartilage repair have been applied. They include lavage, shaving, debridement, laser abrasion, Pridie 
drilling, microfracture techniques and mosaicplasty [4-6].  Novel treatment relying on cell therapies 
and TE has gained substantial importance in the orthopaedic field; however, the complexity of 
interactions between cells, matrix and other factors makes the reproduction of articular cartilage in 
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vitro extremely challenging. Therefore, it is crucial to understand the processes that regulate 
chondrogenesis in order to attempt regeneration of the adult tissue through a defined stimulation of 
specific signaling pathways.  
During limb bud development in the embryo, chondrogenesis of mesenchymal cells is 
regulated through cell-cell adhesion (condensation), cell-cell matrix interaction, biomechanical 
signals and a diversity of growth factors including TGFβ superfamily members- bone morphogenic 
proteins (BMPs), fibroblasts growth factor (FGF), epidermal growth factor (EGF), insulin-like 
growth factor (IGF)-1, parathyroid hormone-related peptide (PTHrP) and Indian hedgehog (Ihh) [7, 
8]. BMPs are involved in almost every aspect of chondrogenesis, from commitment to terminal 
differentiation via regulation of PTHrP/Ihh and FGF pathways in the growth plate [9, 10].  BMPs 
promote Ihh expression triggering the Ihh/PTHrH negative feed-back loop that regulates the onset 
of chondrocyte hypertrophy. FGFs are another group of molecules that cross-talk with BMPs during 
chondrogenesis. FGF antagonizes BMP-4 induced chondrocyte differentiation leading to reduced 
bone size [11]. Additionally, FGF-2 inhibits Ihh expression, promotes hypertrophic differentiation 
and suppresses chondrocyte proliferation [12]. IGF-1 is expressed in the condensing region of the 
developing cartilage as well as in mature cartilage and synovial fluid. IGF-1 also enhances matrix 
synthesis in vitro and in vivo [13-15]. Furthermore, in vitro administration of exogenous IGF-1 
blocks interleukin-1 induced degradation pathways of proteoglycans in chondrocytes [16, 17].  The 
complex interconnected pathways involved in chondrogenesis, cartilage maintenance, and the 
progression of cartilage degeneration have yet to be unraveled.  Further understanding is necessary 
to selectively interfere or control these pathways in order to enhance the long-term stability and 
function of implanted TE cartilage in treating not only injured, but also diseased tissue. 
 
3. Osteoarthritis  
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3.1.  Etiology of OA  
Osteoarthritis (OA) is a debilitating, progressive joint disease often associated with the aging 
process. It represents a combination of several disorders in which biomechanical properties of 
cartilage are altered leading to tissue softening and ultimately degradation [18]. The main 
characteristic of OA is an imbalance between chondrocyte anabolic (synthesis) and catabolic 
(resorptive) activities. The degenerative process may be initiated with the loss of proteoglycans 
from the ECM followed by disruption of collagenous fibrillar network leading to cell 
apoptosis/necrosis and deterioration of the functional tissue. Given that OA is a pathology 
encompassing articular cartilage, subchondral bone, ligaments, capsule, and synovial membrane, 
before any thought can be given to the TE approach, it is necessary to understand the pathways that 
underline the degenerative processes.  
The etiology of OA, although not fully understood, is comprised of several interconnected 
factors: age, programmed cell death (apoptosis), local inflammatory processes and mechanical 
stress.  
 
3.2.  Age related changes – chondrocytes senescence and apoptosis 
Articular cartilage undergoes age-related changes that increase the risk of joint degeneration 
leading to the development of OA [19, 20]. These changes include structural and biochemical 
matrix reorganization, surface fibrillation, alteration in proteoglycan composition, increased 
collagen linking and decreased tensile strength and stiffness [21]. There are well described cellular 
changes associated with aging in different tissues that could also explain the decline of cartilage 
function [22]. The ability of chondrocytes to maintain metabolic homeostasis is shown to decline 
with age [20] leading to alterations in proteoglycan and collagen composition and organization [21, 
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23]. A decrease in cell number and/or biosynthesis could account for these observations. Indeed, 
decreased cell numbers have been reported in OA cartilage, although synthesis of matrix 
macromolecules was not altered in isolated OA chondrocytes grown in monolayer cultures [24].  
Interdependent mechanisms that decrease functionality of cells with age and lead to cell 
senescence include cumulative oxidative damage, accumulation of mutations and genetic instability, 
and telomere shortening [25-27]. In chondrocytes, characteristics of aging include synthesis of 
smaller, more irregular aggrecans accompanied with decreased synthesis of proteoglycans, 
increased expression of senescence-associated β-galactosidase activity, telomere erosion, and 
decreased response to IGF [28-30]. The aging of chondrocytes isolated from healthy cartilage has 
been demonstrated by slower proliferation rates in culture of cells from healthy individuals older 
than 30 years [31]. In addition, glycosaminoglycan content of corresponding micromass pellet 
cultures was lower despite the exposure to growth factors indicating that aging also affects 
chondrocyte ability to respond to growth factors and re-differentiate. Furthermore, chondrocytes 
from normal but aged patients had a secreted protein pattern  resembeling that of chondrocytes from 
OA patients  and not young individuals [32]. Other studies have also shown that the responsiveness 
of aged chondrocytes to growth factors TGFβ, IGF-1 and EGF and cytokine interleukin -1α (IL-
1α) is altered [33-35]. In OA cartilage, expression of β-galactosidase was increased close to 
but not away from the OA damage sites suggesting that cell senescence plays a role in the 
progression of aging cartilage towards disease [36]. In the post-traumatic OA chondrocyte 
senescence was also accelerated [37] and freshly isolated OA chondrocytes were less responsive to 
IL-1β [38] further implicating cell senescence in the development of arthritis.  
Programmed cell death (apoptosis) is an essential mechanism for homeostasis of all tissues. 
A variety of experimental models have demonstrated that chondrocyte apoptosis occurs after 
injurious impact, release of cytokines and nitric oxide (NO), and is related to aging [39, 40]. 
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Although several studies have demonstrated a high rate of apoptosis upon mechanical trauma [41], 
the role of apoptosis in OA remains controversial [42, 43]. While some studies indicated increased 
rates of apoptosis in OA, linked to proteoglycan depletion from the ECM [44, 45], others have 
shown increased apoptosis only in the calcified cartilage layer [46]. Furthermore, apoptosis in 
chondrocytes may be as unique as the tissue itself; a novel term “chondroptosis” has been suggested 
to differentiate classical from chondrocyte-specific apoptotic pathways [47]. Whether as a result of 
injury or aging process, cell death and the consequent inability to repair and maintain cartilage play 
an important role in the development of OA. 
 
3.3.  Cytokines, oxidative damage and chemokines  
Local inflammatory processes within the cartilage itself accompanied with deregulated 
cytokine activities, namely interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) have been 
shown to contribute to pathological development of OA [48, 49]. Cytokines are soluble or cell-
surface molecules that play an essential role in mediating cell-cell interactions. In the normal adult 
cartilage their presence is low as the chondrocytes’ activity is limited to tissue maintenance. In the 
development of OA the delicate balance between matrix synthesis and degradation is perturbed. The 
initial inducers of cartilage catabolism in OA have not been identified. Potential stimuli include 
mechanical stress [50, 51], and degradation products of ECM components including fibronectin 
fragments which stimulate production of matrix-degrading proteases [52-55].  IL-1 is a prototypical 
proinflammatory cytokine implicated in OA cartilage degradation which stimulates production of 
matrix metalloproteinases (MMPs). MMPs are a family of enzymes that degrade collagen, elastins 
and other ECM components [56]. In OA cartilage IL-1 co-localized with MMP1, 3, 8 and 13 and 
other proinflammatory catabolic enzymes [57]. In animal models intra-articular injection of IL-1 
resulted in proteoglycan loss while the inhibition of IL-1 via IL-1 receptor antagonist (IL-1ra) 
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slowed the progression of cartilage loss [49]. TNF-α effects also include stimulation of degrading 
proteinases and suppression of matrix synthesis. Importantly, TNF-α and IL-1 exert synergistic 
effects in enhancing cartilage damage and inhibition of proteoglycan synthesis [58, 59]. Finally, IL-
1 and TNF-α increase nitric oxide synthase leading to an increase of NO [60]. NO radicals have 
deleterious effect in joint cartilage including downregulation of matrix synthesis and upregulation 
matrix degradation via activation of MMPs [61-63]. Furthermore, NO increases chondrocyte 
susceptibility to oxidants while free radicals produced by NO were also shown to induce 
chondrocyte apoptosis [44, 64, 65]. The degradation of aggrecan, the second most abundant 
component of ECM is mediated through another family of metalloproteinases, aggrecanases [66, 
67]. IL-17 was also demonstrated to contribute to the pathology of OA. IL-17 induces collagen 
degradation and NO production in human chondrocytes [68-70]. Recently, IL-17 was found to 
activate not only collagenases MMP 3, and MMP13 but also aggrecanase 1 and thus has been 
proposed as a target for reducing cartilage degradation [71]. Control of MMP activity is achieved 
through tissue inhibitors of metalloproteinases (TIMPs) [72]. Imbalance between MMP activity and 
TIMP inhibition is a characteristic of OA cartilage leading to collagen type II degradation [73]. 
A role for chemokines and their receptors in cartilage degradation in OA has recently been 
reported [74]. Chemoattractive cytokines (chemokines) are a large family of mediators of 
inflammation and immunity closely resembling cytokines [75]. From the major chemokines 
subfamilies (CXC,CC,C, CX3C) human chondrocytes can produce CC and CXC chemokines and 
express their corresponding receptors.  Engagement of these receptors induces the release of matrix 
degrading enzymes such as MMP 1, 3, and 13, and N-acetyl-beta-D-glucosaminidase. Furthermore 
GROalpha, a CXC chemokine acting on CXCR2, can activate an apoptotic pathway in 
chondrocytes that leads to chondrocyte cell death. These findings suggest that chemokines can act 
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as an autocrine or paracrine loop on chondrocytes and can contribute to the pathological patterns of 
OA. 
 
3.4.  Post-traumatic causes of OA  
Injurious and excessive mechanical stress can also result in depletion of proteoglycans and 
damage the collagen network [50, 51]. Mechanical factors leading to joint damage can be viewed as 
factors that either compromise joint protection or excessively load the joint [76, 77]. The first 
category comprises factors increasing joint vulnerability, including malalignment, muscle 
weakness, genetic predisposition, and aging, while the second implicates obesity, certain physical 
activities, and acute trauma. Posttraumatic arthritis can result from irreversible cartilage damage 
sustained at the time of injury, and chronic overloading resulting from articular incongruity and 
instability [78]. Joint injuries shown to invoke posttraumatic OA include direct and indirect joint 
impact loading, meniscal, ligament and joint capsule tears, and intra-articular fractures [79, 80]. The 
chondrocytes’ response to mechanical loading is recognized as an integral component in the 
maintenance of articular matrix homeostasis. The eventual result of inappropriate mechanical 
loading is degradation of ECM although the mechanisms by which the degradation progresses 
initiates are not completely understood. Studies examining the contribution of chondrocyte 
apoptosis to matrix degradation in bovine and human cartilage explants subjected to mechanical 
loads representative of traumatic mechanical injury demonstrated an increase in cell death [81, 82]. 
It has been postulated that chondrocyte apoptosis caused by impact injury could initiate a 
pathogenesis similar to that observed in OA [41]. Several loading regimes have been investigated 
with regards to chondrocyte apoptosis and proteoglycan loss. Cyclic loading of bovine cartilage 
caused cell death, loss of proteoglycans and increase in matrix degradation enzyme MMP-3 [83] 
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while mechanical shear stress applied on human articular cartilage increased the production of 
oxidants leading to pre-mature senescence [28, 37].  
 
4. Cartilage TE in OA? The need for “Tissue Re-engineering” 
 
Joint replacement with the metal joint prosthesis represents the main treatment for the OA 
affected joints. An important drawback of the materials currently used in this treatment is that they 
do not withstand patients’ physical activities and are prone to wear out, loosen and occasionally 
break. Thus, promoting repair very early in the degenerative process is the logical attempt to avoid 
joints replacement. Ideally, the biological signals should be provided in a TE package to diminish 
inflammatory process, initiating the reparative processes and prompting the patient’s own tissue to 
complete the regeneration. The key constituents for successful TE are cells, a carrier such as matrix 
scaffold, signaling molecules and correct mechanical stimuli [84]. Scaffolds support cell infiltration, 
proliferation and subsequent differentiation in response to signaling molecules and mechanical 
stimulation, and can provide initial mechanical strength to a TE construct. Two possible approaches 
for tissue regeneration have been developed – preparation of cells which are subsequently injected 
into the lesion (with or without scaffold) allowing regeneration to occur in vivo, and tissue 
reconstruction in vitro whereby a ready-to-use graft is transplanted into the defect.  
The first approach for cartilage TE has been termed autologous chondrocyte implantation 
(ACI), and has become the dominant clinical cell based therapy for the repair of cartilage lesions 
over the past decade. In this technique, expanded articular chondrocytes are implanted under a 
periosteal flap after surgical debridement of the lesion. ACI has demonstrated excellent short to mid 
term repair [85-88] although the evaluation of longterm repair remains somewhat controversial [4]. 
The second approach aims to produce neocartilaginous tissue combining cells with various 
biomaterials, bioreactor systems and growth factor cocktails [89-94]. Both type of cell-based 
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approaches comprise isolation of cells from a low-load bearing area and subsequent expansion in 
vitro. The enzymatic degradation of extracellular matrix (ECM) during the isolation procedure 
affects cells as demonstrated by their change in gene expression profile [95]. After initial 
attachment, cells start to proliferate, adopt a polygonal morphology and become fibroblast-like. 
Phenotypic changed are accompanied with switches in gene expression, including loss of collagens 
type II, IX and XI and aggrecan and concomitant upregulation of collagen type I, III and V [96, 97]. 
Furthermore, their surface marker profile dramatically changes towards a more mesenchymal 
progenitor-like cell upon prolonged in vitro culturing [98]. The sum of these changes has been 
termed de-differentiation. Several attempts to grow chondrocytes in suspension and overcome de-
differentiation process have been made, including chondrocyte growth on non-adherent plastic 
surfaces [99], in agarose [100, 101] or alginate gels [102]. Although chondrocytes retained their 
capacity to produce ECM, proliferation rates were considerably impaired. 
Various strategies employed to promote re-differentiation of passaged chondrocytes include 
cell growth in three-dimensional (3D)-like cultures such as micromass pellet cultures and natural or 
artificial scaffolds, media supplements including anabolic cytokines and growth factors [103], 
variation in oxygen tension [104] and mechanical stimulation [105]. 
Treatment of cartilage lesions via a TE approach has mostly been employed in small lesions 
resulting from traumatic injuries, and in a younger population. The situation is very different in OA. 
The translation of this form of therapy under degenerative conditions has not yet been successful. 
This can be probably explained by the extent of the disease that affects the OA joint.  Thus, the TE 
approach should address several phenomena including blocking the production of pro-inflammatory 
factors and suppressing the progression of the degenerative process affecting both, cartilage and 
bone compartment. 
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At present only small and contained degenerative lesions could be tentatively treated using 
available TE methods. In the case of extended degenerative conditions, a treatment with currently 
available clinical TE procedure is insufficient and needs further development. The requirements for 
the treatment of extended OA lesion include resetting the entire joint local environment to the 
physiological baseline. To this end a “Tissue Re-engineering approach” that addresses the joint 
resurfacing, inflammation and mechanical issues may offer a successful tissue regeneration. 
 
5. Cell sources for cartilage TE 
To date several cell sources have been investigated as potential candidates for the cell 
therapy based approach for cartilage TE, including normal and OA chondrocytes and mesenchymal 
stem cells (MSC) derived from a variety of tissues. Embryonic stem cells represent a promising cell 
source but many ethical issues need to be resolved prior to their clinical application. All cell type 
candidates are similar in that they have lost their intrinsic “knowledge” of which tissue they need to 
produce, thus identification of growth factors to trigger correct signaling cascades is essential. 
Additionally, several parameters need to be assessed when choosing the cell type including cell 
availability, cellular phenotype comprising gene and protein expression, and cellular capacity to re-
differentiate and produce appropriate cartilaginous ECM.  
Table 1. Cell types for tissue engineering 
Chondrocytes articular 
 auricular 
 septal/nasal 
 costal 
Mesenchymal stem cells bone marrow 
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 adipose tissue 
 muscle tissue 
 peristeum 
 synovial membrane 
Table 1. Cells with chondrogenic capacities to be employed for TE. 
 
5.1.  Chondrocytes 
Chondrocytes are the cells of choice for all current ACI procedures. Adult chondrocytes 
with matrix forming capabilities have been isolated from several sources, including low load-
bearing area of articular joint cartilage, as well as septal, auricular and costal cartilage [106-111]. 
However, due to the process of de-differentiation, growth factors are currently required to activate 
re-differentiation pathways leading to chondrogenesis. The best candidates that could provide 
appropriate signaling are molecules involved in embryonic chondrogenesis, namely members of 
TFGβ family, BMP-2 and BMP-7, and IGF.  
Combination of basic FGF with TGF has been employed to stimulate the process of de-
differentiation in rabbit chondrocytes with the idea to obtain secondary chondroprogenitor cells 
[112]. These chondroprogenitor cells were subsequently able to re-express chondrocyte phenotype 
in vitro and form hyaline cartilage in an in vivo assay. Basic FGF has been demonstrated to increase 
accumulation of proteoglycans of adult canine articular chondrocytes embedded in type II collagen-
glycosaminoglycan scaffold [113]. Studies of the role of TGFβ-1 and BMP-2 in rat periosteal 
chondrocytes cultured in aggregates indicated that while cell treatment with BMP-2 alone results in 
hypertrophy, combined treatment lead to formation of abundant ECM [114], suggesting a role of 
BMP-2 in neochondrogenesis followed by terminal differentiation by TGFβ-1. The hypertrophic 
effect of BMP-2 was confirmed in bovine articular chondrocytes embedded in polyglycolic acid 
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(PGA) scaffold, while BMP-12 and BMP-13 increased growth rate and modulated the composition 
of engineered cartilage. The role of BMP-2, 3, 5, 6, and 7 was assessed in bovine articular 
chondrocytes embedded in alginate in vitro and in a nude mouse model [115]. BMP-7 proved the 
most efficient in stimulating matrix synthesis and in suppressing the infiltrative response of mouse 
fibroblastic cells thereby preventing transplant destruction. In human articular chondrocytes a 
combination of FGF and TGFβ-1 increased cell proliferation rates and also allowed for more 
efficient chondrocytes re-differentiation in pellet cultures [103]. Recently, the role of several 
prostaglandins was evaluated for chondrogenesis of human de-differentiated articular chondrocytes 
[116]. While PGE(2) reduced the expression of collagen type I in pellet cultures, PGD(2) and 
PGF(2) alpha enhanced chondrogenic differentiation and ECM production. 
 
5.2.  OA chondrocytes 
Several limiting factors are associated with the use of chondrocytes from OA joints, 
including the number of cells that can be obtained from a diseased tissue, capacity of cells to 
proliferate in vitro, and responsiveness to growth factors necessary to trigger re-differentiation 
process. Chondrocyte numbers are decreased by 38% in OA cartilage as assessed 
histomorphometrically and via the number of isolated cells [24]. While proliferative capacity of 
chondrocytes in OA cartilage is increased in vitro and may account for chondrocyte clustering 
observed in vivo, results in vitro are still inconclusive given that both lower and higher proliferative 
rates have been reported [32, 117]. Finally, mechanical insult, joint instability and imbalance 
between anabolic and catabolic cytokines lead to altered cellular responses in OA chondrocytes and 
could make them inappropriate for reparative or regenerative therapy [43, 118].  
The gene expression profiles from both healthy and OA chondrocytes indicate an increased 
expression of collagens without changes in their ratios [119]. In contrast, OA chondrocytes express 
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significantly higher levels of matrix degrading enzymes MMP1, MMP2, MMP3, MMP13 and 
aggrecanase-1 [38]. The most striking observation in OA chondrocytes is the synthesis of molecular 
markers characteristic of de-differentiated chondrocytes, namely collagen type I in the chondrocyte 
clusters, collagen type X in the upper zone, and re-expression of collagen type IIA [120]. 
Despite all the identified differences, recent data indicate that OA chondrocytes retain their 
differentiation potential upon isolation and proliferation in vitro [117]. In the micromass pellet 
cultures OA chondrocytes continued to proliferate for 14 days thus increasing the pellet size in 
contrast to normal chondrocytes. The proteoglycan production was comparable to normal 
chondrocytes, and the collagen-rich matrix was present, although the total collagen was 
significantly lower. Additionally, in a 3D-scaffold based on hyaluronic acid, OA chondrocytes were 
also able to produce cartilage-specific matrix proteins. These results raise hope that despite their 
differences in comparison to normal chondrocytes, OA chondrocytes could be employed as a cell 
source for TE treatment providing that the disease can be controlled. Recent data using human 
chondrocytes from patients with the history of trauma, demonstrated that cells exposed to a 
hyaluronan based scaffold reduced apoptosis and decreased gene expression as well as secretion of 
degradation cytokines, namely, MMP-1, and MMP-13, and NO [121]. At the same time, the 
expression of cartilage specific genes SOX9, collagen type II and aggrecan indicated differentiation 
towards chondrogenesis. 
 
5.3.  Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) are self-renewing progenitor cells that have the potential to 
differentiate into chondrocytes, osteoblasts, adipocytes, fibroblasts, and other tissue of 
mesenchymal origin [122, 123]. They reside in many tissues within the adult organism and display 
the capacity to regenerate the cell pool of a given tissue [124-126]. MSC discovery opened new 
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avenues for therapeutic approaches because of their inherent accessibility and repair capacities. 
Several aspects need to be taken into consideration for cell therapies using MSCs: maintenance of 
undifferentiated status during the expansion in vitro, homing mechanisms that guide delivered cells 
to a site of injury and factors that induce and most importantly maintain cell differentiation status in 
vivo.  
Although pluripotency has been demonstrated for MSC derived from bone marrow, adipose 
and muscle tissues as well as synovial membrane [122, 127-130], a growing body of evidence 
indicates that pluripotency  decreases during MSC proliferation in vitro [131, 132].  A large number 
of signaling molecules that coordinate differentiation of MSCs into chondrocytes have been 
extensively investigated. Basic FGF was demonstrated to increase proliferation rate and life span in 
rabbit, dog and human MSC while maintaining their potential to differentiate towards fat, cartilage 
and bone [133, 134]. The family of BMPs has a pivotal role in prechondrogenic condensations and 
the transition of chondroprogenitor cells into chondrocytes [135-137]. Specifically, BMP-2 is 
expressed in the condensing mesenchyme of the developing limb [138], and regulates chondrogenic 
development of mesenchymal progenitors [139-141]. BMPs were demonstrated to induce 
chondrogenesis of MSCs in vitro [142, 143]. An important observation in some of these studies is 
further development towards hyperproliferative state indicating potential final differentiation to 
bone [114, 144]. The exclusive development towards chondrogenesis was observed only upon 
administration of recombinant BMP2 in pellet cultures of human MSC [142].  The exposure of 
equine MSCs to TGFβ-1 resulted in higher collagen II expression in monolayer cultures [145], and 
was superior to the treatment with hyaluronic acid and synovial fluid for chondrogenesis in pellet 
cultures [146]. TGFβ-1 was also demonstrated to induce chondrogenesis in bovine MSCs in pellet 
culture [147]. Insulin growth factors (IGFs) play a central role in chondrogenesis, and IGF-I has a 
potent chondrogenic effect in MSCs [148]. The effects of TGFβ-3, BMP-6 and IGF-1 analysed with 
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human MSC in pellet cultures demonstrated that a combination of TGFβ-3 and BMP-6 or TGFβ-3 
and IGF-1 were more effective for chondrogenic induction [149]. 
The first application of MSCs in cartilage repair was conducted in rabbit where full 
thickness defects were filled with collagen scaffold seeded with MSC and mechanically loaded 
[150]. The shortterm results indicated regeneration of cartilage and bone. In a rabbit model MSC 
transplanted into collagen scaffold impregnated with recombinant BMP-2 enabled cartilage 
regeneration [151]. In a rat model implantation of MSC expressing BMP-2 or IGF-1 efficiently 
filled cartilage defect. Recently, in a murine model, only MSC expressing BMP-2 were shown to 
produce cartilage [152]. Unfortunately, none of the studies could demonstrate long lasting tissue 
formation suggesting that more investigation is needed before MSCs can be used in cartilage 
regeneration.  
Potential use of MSCs has been also investigated in a goat meniscectomy OA model. Local 
injection of MSCs isolated from caprine bone marrow and labelled with green fluorescent protein 
(GFP), together with hyaluronic acid, stimulated regeneration of meniscal tissue and retarded the 
progressive cartilage destruction normally seen in this model of OA [153]. The presence of 
fluorescent cells in the newly formed menisci testified the contribution of MSC to the repair 
process. The results suggest a therapeutical benefit from injection of MSC for the traumatic type of 
injury to the meniscus that could thereby prevent further degeneration toward OA. 
To assess possible application of MSCs in humans, proliferative and differentiation capacity 
of bone derived MSCs obtained from late stage OA patient was compared to bone marrow derived 
MSCs from healthy donors [154]. Cell proliferative potential as well as chondrogenic and 
adipogenic differentiation of MSCs from OA patients in vitro were significantly reduced compared 
with that of the healthy donors. These results suggest a change of bone marrow MSC capabilities in 
OA patients. The mostly osteogenic capacities of OA MSCs could explain the increase in bone 
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density and cartilage loss that are observed in OA patients. Importantly these data incite carefully 
designed and extensive further studies of bone marrow derived MSC from OA patients.   
Previous studies have demonstrated the capacity of isolated, single-cell derived human 
articular chondrocyte clones to differentiate into cartilage, fat and bone [155]. However, these cells 
were not characterized for their surface molecules and not defined as MSCs. A more recent study 
has confirmed that de-differentiated adult human chondrocytes represent a population of 
multipotent cells capable to differentiate into adipogenic, osteogenic, chondrogenic, myogenic and 
neurogenic lineages [156]. Finally, the presence and characteristics of MSCs isolated from the 
cartilage of OA patients were examined [157]. While both MSCs isolated from healthy donors and 
OA patients had a surface marker profile characteristic of MSC, greater number of MSC was 
obtained from OA patients irrespective of whether the donor site was affected by the disease. The 
increased frequency of progenitor cells in OA cartilage could result from increased proliferation of 
resident progenitor cells, de-differentiation of chondrocytes (as demonstrated by their changed 
genetic profile) or from recruitment of MSC from synovial membrane or synovial fluid [130, 158]. 
MSCs have been tested directly for the repair of OA knees in humans [159]. Bone marrow 
derived MSC were expanded in culture, embedded in collagen matrix and transplanted. The follow-
up after 6 months indicated similar clinical aspects in control cell-free and MSC treated lesions, but 
better arthroscopic and histological outcomes. Although promising data were obtained, results from 
long-term studies are still required.   
As outlined above, the major hurdle in the OA treatment is the presence of inflammatory 
cytokines whose action needs to be controlled prior to or in parallel with the reparative attempts. 
Several studies have recently dealt with this issue. Dual expression of IGF-I and interleukin-1 
receptor antagonist (IL-1Ra) were studied in the horse OA model [160]. Cartilage explants were 
exposed to the milieu of monolayer synovial membrane-derived cells expressing IGF-1 and IL-1Ra. 
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The data confirmed that combining the anabolic action of IGF-1 and the catabolic blocking of IL-
1Ra protected and partially restored cartilage matrix. Another study employed gene transfer of 
TIMP-1 into bovine chondrocytes and demonstrated resistance to the catabolic effects of IL-1, 
including reduced MMP activity and a decreased loss of collagen type II [161]. 
 
6. Scaffolds and Bioreactors 
 
6.1.  Scaffolds  
Scaffolds represent one of the key components for the TE approach. Their application 
ranges from a substitution of periosteal flap in the ACI treatment to a drug delivery device that 
could enhance tissue regeneration and reduce the OA related inflammatory processes. 
As an alternative to tissue flaps in the ACI treatment, highly porous scaffolds may be used to 
maintain differentiated cells in a given area, or to encourage proliferation of chondrocytes as a 
technique for regeneration enhancement by encouraging cell migration [162]. Beyond being a 
simple mechanical substrate, the scaffold interacts with cells, bioactive molecules and mechanical 
signals in a dynamic and synergistic manner to contribute to the process of regeneration [163]. The 
main characteristics of an ideal scaffold include sterility, biocompatibility, biodegradability and 
sufficient mechanical properties to support cell differentiation and matrix production. Furthermore, 
the nature and type of defect determining the size and shape of the tissue to be regenerated together 
with the joint conditions of the patient must be taken into consideration when selecting the 
appropriate scaffold [163].   Finally, in the case of OA degeneration the choice of scaffold is 
particularly challenging due to the involvement of other joint tissues, namely synovium and 
subchondral bone, which are also affected by the disease. 
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The unique scaffold properties suited to regenerate bone and cartilage are very different. 
While there are many materials that may be applied for the problem of resurfacing OA joints, we 
will focus on those that have been extensively used, or have shown promising results in the TE 
application.  These materials, in form of matrices, can be broadly categorized according to their 
chemical structure into natural, protein-based polymers, carbohydrate-based polymers, artificial 
materials and combinations thereof (see Table 2). 
 
Table 2. Chemical classes of matrix 
1. Protein-based or natural polymers 
 Fibrin 
 Collagen 
 Laminin (Matrigel) 
 Gelatin 
2. Carbohydrate-based polymers 
 Polylactic acid 
 Polyglycolic acid 
 Hyaluronan 
 Agarose 
 Alginate 
 Chitosan 
3. Artificial polymers 
 Dacron (polyethylene terphtalates) 
 Teflon (Polytetrafluoethylene) 
 Carbon fibers 
 Polyestherurethane 
 Polybutyric acid 
 Polyethymethacrylate  
 Hydroxyapatite 
4. Within/between classes 
 Cross Linkage 
 Chemical modification 
 Geometrical modifications 
 Matrix combinations 
Table 1. Classes of scaffolds used for joint resurfacing.  
Protein-based, natural polymers may contain ligands that can be recognized by cell-surface 
receptors and have the advantage of known biocompatibility and fewer regulatory constraints. 
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Potential drawbacks of these materials include lack of large quantities for clinical application, 
difficulty of processing into scaffolds, concerns of immunogenicity, disease transfer for allografts, 
and varied degradation rate from the patient.   
 The natural polymer that has received the most attention is collagen. In 1983, it was found 
that chondrocytes seeded on collagen gels maintain differentiated phenotype and GAG production 
for six weeks [164]. Wakitani et al. have reported that when MSCs were seeded into collagen gels 
implanted in osteochondral defects in rabbits, embryogenesis was recapitulated and both bone and 
hyaline cartilage were formed [150].  However, mechanical properties of the regenerated tissue 
were significantly lower compared to normal tissue, and evidence of degeneration was detected 
after 24 weeks ([3, 150]). Collagen matrices have also been found to stimulate new collagen 
production by transplanted cells as compared to other scaffolds [165]. In a recently published study, 
porcine collagen membrane was combined with microfracture to repair osteochondral defects in a 
sheep model with good results. Further improvement was achieved by seeding autologous 
chondrocytes onto the collagen membrane [166]. Methods that can demonstrate substantial repair of 
lesions involving both cartilage and subchondral bone may provide future promise to the possibility 
of repairing at least localized OA lesions.  Collagenous matrices or collagen-imitating scaffolds are 
increasingly emerging as highly suitable vehicles for cell and growth factor transport into cartilage 
lesions. Collagens represent not only major constituents of connective tissues in terms of integrity 
and function, but are also major targets of tissue destruction and regeneration and thus might 
become major tools to achieve tissue repair [167]. 
Another protein-based candidate for osteochondral repair is fibrin glue, produced by 
polymerization of fibrinogen with thrombin [168]. Fibrin matrix was used as support for 
chondrocytes in full-thickness articular cartilage defects in horses, and regeneration of cartilage 
with a surface of hyaline-like tissue containing high percentage of type II collagen and sulphate 
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GAGs was achieved [169]. However, fibrin is proinflammatory and induces its own degradation 
further leading to its substitution by cellular components within the extra-vascular tissue. Its 
degradation products are however physiological and thus non-toxic although there are reports 
questioning its immunogenecity [170].  Further, the application of fibrin glue in replacement of 
structural tissues is limited by its lack of mechanical stability. 
Synthetic polymers are available in unlimited supply and are easily processed into desired 
shapes and sizes. These materials are versatile because their physical, chemical, and degradation 
properties may be modified to meet the specific requirements of a given application. Copolymers, 
polymers blends and composites with other materials may also be manufactured to impart desired 
properties for certain applications.  
Polylactic/polyglycolic acids, both individually and in combination have been investigated 
as scaffold material to repair cartilage defects for more than two decades [3, 94, 168, 171, 172]. 
Structural modifications to these polymers have yielded different matrix properties ranging from 
fine fibrillar meshworks to foam [173]. Compared to fibrin, collagen, Poly(L-lactic acid) (PLLA), 
and poly (DL-lactic-co-glycolic acid) (PLGA), PGA was shown to provide a better scaffold for in 
vitro cartilage regeneration, as demonstrated by cell densities equivalent to those found in natural 
tissues, and by continuous cellular production of type II collagen [174]. Although such engineered 
constructs have also been tested for articular cartilage repair in animal models, mainly in rabbits 
[94, 171, 175-177]), they have not been applied in human patients. The possible reasons include the 
graft induction of foreign body giant cell reaction [100] and the hydrolytic activity of the polymer 
substrate, which yields both toxic and partially cytotoxic degradation products. These potentially 
deleterious effects have, as yet, not been thoroughly investigated. A recent efficacy study for drug 
delivery using PLA microspheres in the 35-105 micron size range, loaded with 20% Paclitaxel, a 
chemotherapeutical agent resulted in Paclitaxel release in a controlled manner over several weeks in 
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a rabbit model [178]. Thus local drug delivery approach using PLA scaffold may be a potential 
formulation for the intra-articular treatment of inflammation in arthritic conditions. Triptolide, an 
immunosuppressive drug was also studied in a collagen induced arthritis rat model and 
demonstrated positive curative effect [179]. 
 Hyaluronan is a physiological component of the articular cartilage matrix. It forms 
macromolecules of remarkable length and molecular weight which are biocompatible and 
biodegradable [180]. In theory, hyaluronan would be an ideal matrix to support cartilage repair if it 
could be implanted in an unmodified form. However, in order to achieve the required matrix 
physiochemical properties and structural organization, hyaluronan is in practice cross-linked by 
esterification or other means [180] resulting in compromised biocompatability [181]. Matrices 
composed of hyaluronan have not been applied alone to enhance spontaneous repair responses, but 
were frequently used as carriers for chondrocytes or bone marrow derived MSC in the treatment of 
cartilage defects of the knee [182]. In a recent review Marcacci has reported results from a 3 year 
clinical study of a cohort of 141 patients suffering from acute cartilage defects treated with an 
implant composed of a esterified derivative of hyaluronic acid (HYAFF 11) seeded with 
chondrocytes [183]. At the follow-up 91.5% of patients improved their condition according the 
International Knee Documentation Committee subjective evaluation; 76% and 88% of patients had 
no pain or mobility problems as assessed by the EuroQol-EQ5D. Hyaluronic acid based 
biomaterials have also been shown to create an environment in which the cells downregulated the 
expression of catabolic factors. Decreased levels of MMPs and NO were observed in the 
supernatants of chondrocytes grown on hyaluronan-based scaffolds, and cell apoptosis decreased 
during the culture period [121]. The results demonstrated a potential ability of hyaluronan scaffold 
to reduce the production of molecules involved in cartilage degenerative diseases and may indicate 
its beneficial effect in the treatment of early OA lesions.  Modulation of the inflammatory cascade 
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by the intrinsic scaffold physical/chemical properties may prove to be of major importance in OA 
treatment strategies. An alternative concept is based on gene-activated matrices, where a specific 
gene is locally delivered in order to enhance healing or block degenerative/inflammatory processes 
[184].  
Medicine today is continually adopting less invasive procedures that reduce morbidity and 
length of hospital tenure, while increasing the pace of recovery and return to normal activity. This 
trend towards minimally invasive procedures has also reached the field of TE and is a source of 
motivation for development of injectable cartilage engineering systems [185]. As a part of such 
system the scaffold must have physical properties that would allow an injection via a syringe or 
catheter. Once implanted, the scaffold material should solidify, acquire necessary mechanical 
properties and maintain a desired form and shape in a specific location without diffusion or 
movement[186]. Hydrogels are a class of materials that satisfy the requirements for a successful 
injectable TE system.  Examples of injectable hydrogel systems that have been employed in TE 
include Pluoronics®, a block copolymer of polyethylene glycopolypropylene glycol [187], collagen 
[166], Matrigel TM [188], an ECM extract derived from a solubilized basement membrane 
preparation extracted from EHS mouse sarcoma, and fibrin glue [189]. The injectable polymer 
systems that crosslink via physical interactions are simple to apply as no external initiator or cross 
linking agent is required for the hydrogel formation. Unfortunately, hydrogels created from 
physically cross linked polymer often suffer from weak mechanical properties that limit their 
application [190].  A summary of injectable material is listed in Table 3. Given that OA is a 
generalized degenerative disease, an additional role of injectable hydrogels would be to deliver 
regulatory factors to the joint while providing resurfacing capabilities.  
Table 3. Injectable scaffold biomaterials for cartilage tissue engineering 
Natural Materials  
 Alginate 
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 Collagen 
 Fibrin glue 
 Hyaluronic acid (crosslinked) 
 Chondroitin sulfate 
Synthetic materials  
 PLG speheres 
 PEG 
 Polyvinyl alcohol 
 Polypropylene fumrate 
  
Table 3. Natural and synthetic materials applied as a liquid for injectable TE system. 
PEG:polyethylene glycol; PLG: Poly(lactide-coglycolide) 
 
 
6.2. Bioreactors for cartilage TE 
The term “bioreactor” in the context of cell and tissue culture indicates a device where 
specific physicochemical culture parameters can be reproducibly maintained at defined levels. By 
providing inherent control over the required bioprocesses, the use of bioreactor systems has the 
potential to improve the quality of engineered cartilage tissues and to streamline their manufacture. 
Moreover, bioreactors are expected to play a key role in the establishment of advanced model 
systems to investigate mechanisms of cartilage degeneration and repair, and possibly to predict the 
behaviour of engineered grafts upon implantation into an OA joint. 
 
6.2.1. Bioreactors to establish and maintain 3D cultures 
The initial step in the ex vivo generation of a cartilage graft, namely the seeding of 
chondrogenic cells onto a porous scaffold, establishes the three-dimensional environment and likely 
has a strong influence in determining the uniformity of successive tissue formation. Simply 
pipetting a highly dense cell suspension into the porous scaffold is the most commonly used seeding 
technique, but the manual and user-dependent process lacks control and reproducibility. Stirred-
flask “bioreactors” can increase the control and reproducibility of the process when seeding cells 
into thin and highly porous scaffolds [191]. However, due to insufficient penetration of cells into 
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the interior region of thick or less porous scaffolds, stirred-flask systems can also yield low seeding 
efficiencies and non-uniform cell distributions, with a higher density of cells lining the scaffold 
surface [192]. Perfusing a cell suspension directly through the pores of a 3D scaffold using a direct 
perfusion bioreactor was shown to be more effective and reproducible in generating uniformly 
seeded constructs than the above techniques, in particular when seeding thick and low porosity 
scaffolds [192]. 
After distributing the chondrocytes throughout the porous scaffold, a key challenge is to 
maintain this distribution and the cell viability within the internal region of the construct during 
prolonged culture. Due to mass transfer limitations, cartilaginous constructs cultured under 
conventional static conditions (i.e., with unmixed culture media) are frequently inhomogeneous in 
structure and composition, containing a hypoxic necrotic central region and dense layers of viable 
cells encapsulating the construct periphery. Stirred-flask and rotating vessel bioreactor systems have 
been shown to enhance mass transport to/from chondrocyte-scaffold constructs, thus resulting in 
tissues with increased fractions of cartilage-specific molecules in the inner core [193]. Interestingly, 
as compared to the turbulent flow within stirred flasks, the dynamic laminar flow in rotating wall 
vessels, associated to reduced levels of shear, supported the formation of cartilaginous tissues 
containing higher amounts of more uniformly distributed GAG and collagen [191]. Bioreactor 
systems applying a direct perfusion of culture medium through the scaffold pores can also mitigate 
mass transfer limitations throughout the engineered constructs. Perfusion of chondrocyte-seeded 
scaffolds was shown to support elevated GAG synthesis and retention within the ECM, [194, 195] 
as well as a uniform distribution of viable human chondrocytes as indicated in Figure 1[196]. In 
conjunction with computational fluid dynamics modeling of the fluid-induced shear stresses and 
mass transport within the porous architecture of the 3D scaffold [197, 198], a perfusion system can 
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provide a well-defined physicochemical culture environment which has great potential to generate 
cartilage grafts of clinically relevant size. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (a) Perfusion bioreactor system for the engineering of clinically relevant-sized cartilage 
grafts. Culture media is perfused through the pores of the cell-seeded 3D scaffold to reduce mass 
transfer limitations throughout the engineered construct. (b) Cartilage constructs generated under 
static culture conditions are frequently inhomogenous in structure, with cells and matrix 
concentrated at the construct surface and a necrotic interior region. (c) In contrast, cartilage 
engineered using the direct perfusion bioreactor was shown to be highly uniform, with cells and 
matrix distributed throughout the entire graft. Scalebar is 1mm. [196]  
 
6.2.2. Bioreactors for mechanical conditioning 
Physiological joint loading plays a critical role in differentiating MSC during cartilage 
development, and in developing and maintaining the structural and functional properties of articular 
structures in youth and adulthood [199, 200]. Thus, it is not surprising that mechanical loading, 
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applied using a variety of devices [201] has been included as a key element in cartilage TE 
strategies, in order to enhance cell differentiation and/or tissue development in vitro. Indeed, a 
number of studies have reported stimulated chondrocyte metabolism and/or enhanced cartilage 
matrix production in response to dynamic loading, although these responses were greatly dependent 
upon the specific magnitude and/or frequency applied [105, 202-207]. Despite these numerous 
proofs of principle that mechanical conditioning can upregulate gene expression and tissue 
development, little is currently known about which specific mechanical forces, or regimes of 
application (i.e. magnitude, frequency, continuous or intermittent, duty cycle), are most stimulatory. 
The field is further complicated by the fact that the effects of mechanical stimuli on tissue 
engineered cartilage may vary substantially using different scaffold systems [208] or constructs at 
different stages of development [209]. Moreover, a crucial issue that still remains to be 
demonstrated is whether in vitro mechanical preconditioning of engineered cartilage would result in 
grafts with increased chances of long-term in vivo success [210]. 
 
6.2.3. Bioreactors for controlled model systems 
The role of bioreactors for mechanical conditioning of cartilaginous constructs could be 
broadened beyond the conventional one of enhancing cell differentiation and/or ECM deposition in 
engineered tissues. They could also serve as controlled in vitro models to study pathophysiological 
interactions between physical forces and soluble factors on engineered cartilage development. For 
example, a bioreactor applying controlled regimes of loading and specific inflammatory cytokines 
(e.g., IL-1β or TNF-α) might be used to investigate the response of an engineered tissue to an 
environment simulating an OA joint, before more complicated and costly large size animal models 
are introduced.  
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In the context of the identification and validation of effective drugs for OA, the bioreactor-
based reproducible generation of cartilaginous tissues under standardized conditions would offer the 
possibility to use engineered cartilage as a 3D model system for drug screening. Exposure of the 
engineered constructs to defined stimuli (biochemical or biomechanical) could also lead to the 
identification of anabolic targets, which represents a key step in drug discovery. 
 
6.3.4. Bioreactors for cartilage tissue manufacture 
One of the major challenges to bring an autologous cell-based engineered cartilage product 
into routine clinical practice including the treatment of OA would be to translate research-scale 
production models into clinically applicable manufacturing designs that are reproducible, clinically 
effective, and economically acceptable while complying with Good Manufacturing Practice (GMP) 
requirements [211]. Bioreactors have the potential to meet this challenge by automating and 
standardizing the manufacture of engineered grafts in controlled closed systems [212, 213].  
 
7. Mechanical stimulation  
Physiological joint loading is essential for the development and maintenance of normal 
articular cartilage.  During development, both movement and mechanical load play a critical role in 
differentiating embryonic MSC into chondrocytes leading to development of the articular surface 
[199, 214].  In young humans, morphological properties of articular structures are further defined 
(or developed) by mechanical loading of the joints [199, 200].  Even in adulthood, physiological 
joint loading is necessary and responsible for the maintenance of articular structures and leads to 
varying mechanical properties between different joints and within each joint [200, 214].  Variations 
in loading have been shown to alter gene expression, chondrocyte density, and biosynthetic 
response thereby resulting in different organization schemes of the constituents within the ECM 
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[199, 200, 214]. For example, regions such as the patellofemoral articulation that are subjected to 
high shear loads possess a high concentration of collagen fibrils in the superficial layer of the 
cartilage that are aligned in the direction of shear loading [199].     
Given the importance of mechanical loading in the development and maintenance of native 
articular cartilage, it is not surprising that mechanical stimulus can have a significant impact on the 
behavior of isolated chondrocytes (or chondrocytes cultured in vitro), cartilage explants, and tissue-
engineered cartilage constructs in vitro [202, 206, 215].  Functions of mechanical stimulus for in 
vitro tissue systems include control of cell phenotype, delivery of nutrition and removal of waste 
products, and mediation of the synthesis and organization of matrix molecules.  For a synopsis of 
methods used to apply mechanical load to cells in vitro, see the review by [201].  Increases in the 
synthesis of type II collagen, proteoglycan, and other important matrix molecules have been 
accomplished by mechanical preconditioning tissue-engineered constructs [206, 215, 216]. Further, 
mechanical properties of scaffold-based tissue-engineered constructs such as aggregate modulus 
[206], tensile modulus [217], dynamic stiffness and oscillatory streaming potential [216] have been 
shown to increase significantly with mechanical preconditioning.  The efficacy of increasing the 
mechanical properties of repair cartilage tissue with respect to its long-term success in vivo is not 
well understood [210, 218] and remains to be demonstrated.   
 
8.  Outlook of combined TE parameters in the treatment of OA 
The key element in TE approach is to employ biologically based mechanisms in order to 
achieve repair and healing of damaged and diseased tissues. Chondrocytes from normal as well as 
OA cartilage may be suitable candidates as a cell source while pluripotent mesenchymal cells 
isolated from different tissues have also demonstrated the capacity to produce cartilaginous tissue. 
A wide range of natural and synthetic scaffolds have been demonstrated to support cells 
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proliferation and subsequent differentiation. Different types of bioreactors were successfully 
employed to establish and maintain 3D culture systems, provide mechanical conditioning and 
enhance tissue regeneration. Finally, knowledge of action of growth factors, cytokines, chemokines, 
protease inhibitors, and kinases has shed light for the crucial signaling cues in articular cartilage 
regeneration. Can this knowledge be applied for the treatment of OA? 
The first goal in treating OA is to arrest and if possible reverse its progress regionally or 
globally. The TE approach should thus be designed as a “Tissue-Reengineering” to block the 
ongoing inflammatory process while stimulating the regenerative process (Figure 2). For this 
purpose application of a combination of growth factors is essential. Selected growth factors could 
be integrated as a part of the treatment in several ways: i) as recombinant proteins supplied together 
with cells (for example during ACI procedure), ii) as recombinant proteins impregnated in the 
scaffold, or iii) as genes expressed by genetically modified cells. Scaffolds, such as HIAFF11, that 
support reduction of inflammatory cytokines will certainly prove beneficial for the OA treatment. 
Importantly, due to the disease spreading the subchondral bone, that compartment should also be 
included in the treatment. Finally, proper timing for the treatment, in the case of OA as early as 
possible, may prove crucial for successful TE application in treatment of OA lesions.  
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Figure 2. Cartilage tissue re-engineering. Schematic presentation of a potential treatment for OA 
lesions. Stem cells with the potential to regenerate cartilaginous tissue can be obtained from bone 
marrow, muscle, fat, synovial membrane and cartilage, and expanded in monolayer cultures until 
sufficient cell numbers are obtained. Subsequently, cell could be combined with scaffolds and 
growth factors, and either directly injected in the lesion (ACI) or further grown in bioreactors in 
vitro to form new tissue. Neocartilage would finally be implanted in the lesion. All implantation 
procedures would include anti-inflammatory factors in order to decrease further degeneration of the 
joint. 
 
Although TE approach has demonstrated promising results in vitro, new challenges will 
emerge with its translation into the clinical setting. To increase the chances for success, further 
research must address immunological issues (depending on the cell source – autologous or 
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heterologous), integration of the engineered cartilage into the patient’s own tissue and the 
variability of tissue development depending of potentially diseased surrounding tissue, age and 
physical activity. 
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